83.59  0.81 (0.98%)		05-21 15:38
Open: 80.91 High: 84.77 Volume: 474,464		Pre. Close: 82.78 Low: 79.77 Market Cap: 649(M)

Short term
Mid term
Targets	6-month :	107.91	1-year :	126.04
Resists	First :	92.38	Second :	107.91
Pivot price	83.12
Supports	First :	80.05	Second :	72.43
MAs	MA(5) :	78.75	MA(20) :	84.61
	MA(100) :	81.81	MA(250) :	61.57
MACD	MACD :	-1.2	Signal :	-0.4
%K %D	K(14,3) :	45.1	D(3) :	29.3
RSI	RSI(14): 51.6
52-week	High :	123.75	Low :	23.17

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DRUG ] has closed below upper band by 45.2%. Bollinger Bands are 9.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	83.36 - 83.92	83.92 - 84.42
Low:	75.69 - 76.36	76.36 - 76.97
Close:	81.69 - 82.8	82.8 - 83.81

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Wed, 20 May 2026
Piper Sandler raises Bright Minds stock price target on program progress - Investing.com

Tue, 19 May 2026
[6-K] BRIGHT MINDS BIOSCIENCES INC. Current Report (Foreign Issuer) | DRUG SEC Filing - Form 6-K - Stock Titan

Fri, 15 May 2026
Vestal Point (DRUG) and Ryan Wilder report 492,319 shares, 5% stake - Stock Titan

Fri, 15 May 2026
Janus Henderson (DRUG) discloses 1.28M shares, 13.1% stake - Stock Titan

Fri, 08 May 2026
Bright Minds Biosciences (DRUG) to Release Earnings on Friday - MarketBeat

Sun, 26 Apr 2026
How Bright Minds Biosciences Inc. (DRUG) Affects Rotational Strategy Timing - Stock Traders Daily

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	10 (M)
Shares Float	7 (M)
Held by Insiders	11.5 (%)
Held by Institutions	92.6 (%)
Shares Short	751 (K)
Shares Short P.Month	704 (K)

EPS	-2.01
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	8.39
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-15.8 %
Return on Equity (ttm)	-27 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-13 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-41.8
PEG Ratio	0
Price to Book value	10.01
Price to Sales	0
Price to Cash Flow	-63.21

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.